Equity Profile

IRON

Disc Medicine, Inc.

Health CareBiotechnology$2.6B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market traction and effectiveness in commercializing its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IRON Q2-2026 Earnings Preview

Context

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders. As part of the health care sector, its work is crucial in addressing unmet medical needs and advancing treatment options in a specialized field.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.84%

Avg Stock Reaction

+0.34%

Last Quarter Recap

In the last quarter, Disc Medicine reported an EPS of -$1.65, which was a larger loss than analysts expected. The stock saw a slight decline of 0.07% the following day, indicating market disappointment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has struggled to meet earnings estimates in recent quarters. Investors are looking for signs of improvement in both profitability and revenue growth.

Bull Case

If Disc Medicine can show a smaller loss than expected and provide positive updates on its drug pipeline, it could boost investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company reports a larger loss or fails to provide clarity on its future prospects, it could lead to further declines in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be this quarter, and how does it compare to previous quarters?

Given the company's recent history of missing EPS estimates, this figure will be critical in assessing whether the company is making progress.

What updates can management provide on the drug pipeline and upcoming clinical trials?

Investors will be keen to understand the potential for future revenue and the company's strategic direction.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for a smaller EPS loss due to recent improvements in operational efficiency.

Supporting Evidence

The options market is pricing in a 22.14% move, suggesting heightened expectations that could lead to a surprise.

Insider selling may indicate a lack of confidence, but it could also reflect personal financial planning rather than company performance.

The historical trend shows that the stock has reacted positively to smaller-than-expected losses in the past.

Key Risk

If the EPS comes in better than -$1.50, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether the company can stabilize its financial performance and regain investor confidence.

Bull Confirmed If

An EPS loss of less than -$1.50 would signal improved financial performance.

Bear Confirmed If

An EPS loss greater than -$1.70 would reinforce concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±22.14%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±22.1% while IRON has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

32.9%

Calls (200)P/C Ratio: 1.00Puts (200)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$841,283.01

12,388 sh

2 insiders

Net

$841,283.01

Net selling

Most Active Insiders· 4 open-market trades

Chief Financial OfficerFranchi Jean M.
$460,834.05

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Disc Medicine beats expectations, history suggests the stock could rise by around 2.8%, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

A miss could lead to a decline of approximately 0.64%, further dampening investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on any advancements in clinical trials for key therapies.
2Management's outlook on revenue growth and market opportunities.
3Updates on R&D spending and its impact on future product launches.
4Any changes to the company's strategic direction or partnerships.
5Insights into operational efficiencies that could improve profitability.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market traction and effectiveness in commercializing its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IRON Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.84%

Avg Stock Reaction

+0.34%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has struggled to meet earnings estimates in recent quarters. Investors are looking for signs of improvement in both profitability and revenue growth.

Bull Case

If Disc Medicine can show a smaller loss than expected and provide positive updates on its drug pipeline, it could boost investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company reports a larger loss or fails to provide clarity on its future prospects, it could lead to further declines in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be this quarter, and how does it compare to previous quarters?

Given the company's recent history of missing EPS estimates, this figure will be critical in assessing whether the company is making progress.

What updates can management provide on the drug pipeline and upcoming clinical trials?

Investors will be keen to understand the potential for future revenue and the company's strategic direction.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for a smaller EPS loss due to recent improvements in operational efficiency.

Supporting Evidence

The options market is pricing in a 22.14% move, suggesting heightened expectations that could lead to a surprise.

Insider selling may indicate a lack of confidence, but it could also reflect personal financial planning rather than company performance.

The historical trend shows that the stock has reacted positively to smaller-than-expected losses in the past.

Key Risk

If the EPS comes in better than -$1.50, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether the company can stabilize its financial performance and regain investor confidence.

Bull Confirmed If

An EPS loss of less than -$1.50 would signal improved financial performance.

Bear Confirmed If

An EPS loss greater than -$1.70 would reinforce concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±22.14%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±22.1% while IRON has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

32.9%

Calls (200)P/C Ratio: 1.00Puts (200)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$841,283.01

12,388 sh

2 insiders

Net

$841,283.01

Net selling

Most Active Insiders· 4 open-market trades

Chief Financial OfficerFranchi Jean M.
$460,834.05

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Disc Medicine beats expectations, history suggests the stock could rise by around 2.8%, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

A miss could lead to a decline of approximately 0.64%, further dampening investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on any advancements in clinical trials for key therapies.
2Management's outlook on revenue growth and market opportunities.
3Updates on R&D spending and its impact on future product launches.
4Any changes to the company's strategic direction or partnerships.
5Insights into operational efficiencies that could improve profitability.